Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Studies were carried out on patients with adverse reactions to aspirin, paracetamol, phenacetin, codeine, dihydrocodeine, some pyrazolone derivatives, and indomethacin. Three clinico-pathological forms of adverse reactions received particular attention: (1) Asthma, with or without manifestations of systemic anaphylaxis; (2) Serum-sickness-like syndrome; (3) Lymph node enlargement with histological features simulating lymphoma or Hodgkin's disease, which occurred in patients receiving phenylbutazone in particular. A variety of immunological investigations, including some in vitro correlates of immediate- or delayed-type allergy, were carried out. The three syndromes seemed to be associated with immediate-type (or immediate-type-like), immediate-type plus delayed-type, and delayed-type allergy, respectively. In most of the patients with immediate-type-like reactions, and where immunological mechanisms were apparently not involved, pharmacological mediators, particularly histamine, were released from their leucocytes when challenged in vitro with the causative agent(s). This suggested that the main underlying abnormality of their asthma or peripheral vascular manifestations was a direct release of mediators by the drugs, i.e. some type of idiosyncrasy. The causative mechanism of this abnormality has not been established yet.
 ...
PMID:Immunological and non-immunological mechanisms of some of the desirable and undesirable effects of anti-inflammatory and analgesic drugs. 6 51

Possibilities and limits of radiotherapy are described in a survey in the following diseases: Undifferentiated cell leucoses: The radiotherapy of the central nervous system brings an increase of the 5-year survival rates, since the localisations in this region existing in 45-70% are only insufficiently reached by the cytostatic substances because of the defective blood-liquor passage. On the other hand, other indications to radiotherapy recede into the background. Chronic leucoses: In the foreground of the application is the ray-therapy of the spleen, of which, apart from the local effect on the splenic tumour, also an improvement of the remission rates is expected. At adequate indication also the ray-therapy of infiltrates in the lymph nodes and other localisations achieves good palliative results. The extra-corporeal irradiation of blood is a method, the usability of which must still be proved. With the introduction of the modern cytostatic drugs the exposure of the whole body has lost significance. Lymphogranulomatosis: In this disease the radiotherapy has caused a decisive change: In these cases the recognition of the local development of the disease and its continuous spreading was decisive, and issuing from this also the simultaneous irradiation of the defluxion areas and the application of an oncolytic dose. According to the stage with or without combination of cytostatic drugs an exact plan of therapy is made. Here healing rates of 70-80% in stage I are to be expected. Myeloma: Here the radiotherpy has palliative tasks, with correct indication good effects are to be expected. Polycythaemia vera: In this disease radiotherapy in form of incorporation of radioactive phosphorus is the remedy of choice.
 ...
PMID:[Radiotherapy of hematologic diseases]. 6 Aug 34

B-DOPA (Bleomycin (B), D-imidazole carboxamide (D), Oncovin (O), Prednisone (P), Adriamycin (A) is a program developed for the treatment of Hodgkin's disease resistant to MOPP therapy. Twenty unselected patients were treated by the following dose schedule: B, 4 mg/m2 days 2 and 5; D, 150 mg/m2 days 1 to 5; O (vincristine), 1.5 mg/m2 days 1 and 5; P, 40 mg/m2 days 1 to 6; A, 60 mg/m2 day 1. Each course, was repeated at 3 to 4 week intervals to maximum adriamycin dose of 450 mg/m2. All patients had received prior MOPP therapy and six had received prior radiotherapy. Fifteen of the 20 patients entered into the study were evaluable for response. There were nine (60%) complete responders and three (20%) partial responders. The median duration of complete remission was 14+ months with six of nine patients remaining in remission to a maximum of 21 months. The median survival of the nonresponders was 3 months. B-DOPA is an effective combination chemotherapy regimen for advanced Hodgkin's disease in patients who have previously received MOPP treatment, including patients who are refractory to MOPP therapy. The B-DOPA program or modifications thereof, may be integrated into primary treatment programs for advanced Hodgkin's disease.
 ...
PMID:New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease. 6 97

117 patients with stage IIIA Hodgkin's disease were randomly allocated for treatment in a multicentre trial comparing the results of total nodal irradiation (T.N.I.) with those of combination chemotherapy. Staging procedures for most patients included laparotomy; a few patients whose staging did not include laparotomy were studied separately. Of the 81 patients staged by laparotomy, 40 out of 42 (95%) achieved complete remission (C.R.) after treatment by T.N.I. and 29 out of 39 (74%) achieved C.R. during treatment with mustine hydrochloride, vincristine ("Oncovin"), procarbazine, and prednisone (MOPP) (P=0.018). An analysis of the disease-free survival up to four years favoured the group of patients treated by T.N.I. (P less than 0.01) but differences in overall survival were not statistically significant. In the 36 patients with presumed IIIA disease whose staging did not include laparotomy no significant differences in the incidence of C.R. or rates of disease-free or overall survival were observed. It is concluded that T.N.I. is the optimum initial treatment for patients with IIIA disease whose staging includes laparotomy.
 ...
PMID:Initial treatment of stage IIIA Hodgkin's disease. Comparison of radiotherapy with combined chemotherapy. British National Lymphoma Investigation. 6 65

A new four-drug combination chemotherapeutic regimen (BVDS) was used in the treatment of advanced Hodgkin disease resistant to MOPP (mechlorethamine hydrochloride, vincristine sulfate, procarbazine hydrochloride, and prednisone). The BVDS regimen, consisting of 12 cycles of bleomycin sulfate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and streptozocin (streptozotocin), was administered to ten patients. Responses were seen in five (50%) of these patients. Complete remissions occurred in three (30%). These results suggest that BVDS is an effective alternative regimen to MOPP, and may be of benefit not only to patients resistant to MOPP, but also to newly-diagnosed patients with advanced hodgkin disease when combined sequentially with MOPP.
 ...
PMID:A new combination chemotherapy for resistant Hodgkin disease. 6 54

Sixteen patients with Hodgkin's (10) and non-Hodgkin's (6) lymphoma were treated by the "ABCD scheme", which is a combination of adriamycin (25-30 mg/m2 day 1), bleomycin (15 mg day 1-5), CCNU (60 mg/m2 day 1) and DIC (90-100 mg/m2 day 1-5). 15 results are evaluable and included 5 complete remissions, 5 partial remissions, 2 stabilizations, 2 progressions and 1 early death (remission rate: 66%). 45 ABCD courses were given. 8 patients received more than one course (maximum 7 courses). Toxicity was tolerable and consisted mainly of myelodepression, nausea, vomiting and muco-cutaneous alterations. Two patients died following toxicity, one from myelosuppression and the other from interstitial pulmonary fibrosis. The results suggest that this combination can be useful where the usual chemotherapy combination fails.
 ...
PMID:[Simultaneous combination of adriamycin, bleomycin, cyclohexyl-chloroethyl nitrosourea with dimethyl-triazeno imidazole carboxamide in the treatment of Hodgkin's lymphoma]. 6 45

Histochemical markers were used to identify the various cellular and structural components of the human spleen, and to investigate the histogenesis of the splenic lesions of Hodgkin's disease. The early lesions appear in areas near the central artery (periarterial lymphatic sheath) in the white pulp. The white pulp becomes hypertrophic. The lesions enlarge, extend into the red pulp, and compress the sinuses and the cords of Billroth. The derivations of various "histiocytes" contained with the lesions are differentiated by using cytochemical stains for lysosomal enzymes and for granulocytes. The epithelioid cells in the granulomas are rich in those lysosomal enzymes typically seen in phagocytic histiocytes, suggesting that they are indeed true histiocytes. The malignant "histiocytes," including the mononuclear Hodgkin cells, the binucleated Sternberg-Reed cells, and the multinucleated giant cells, do not contain significant amounts of lysosomal enzymes and more closely resemble stimulated lymphocytes. The splenic lesions in Hodkin's disease may be the result of a lymphocytic and histiocytic cellular response to an unknown agent, which reaches the spleen through the central artery in the white pulp.
 ...
PMID:Histogenesis of splenic lesions in Hodgkin's disease. 6 41

Neoplastic tissues from 75 adults with non-Hodgkin's malignant lymphoma were examined for B and T lymphocyte surface markers. All nodular lymphomas were B-cell type. Of 40 diffuse lymphomas, 23 were B, 5 were T, and 12 were "null" type. Patients with nodular lymphoma survived significantly longer than those with diffuse lymphoma (P = 0-00003). For patients with diffuse lymphoma, however, surface markers provide prognostic information not obtainable by histological classification as "poorly differentiated lymphocytic" or "histiocytic". Patients whose malignant cells had B markers survived significantly longer than those whose malignant cells had no markers (P=O-008). Survival of patients with diffuse lymphoma was best predicted by a classification utilising both surface markers and histological appearances. Differences in survival among patients with B-cell and "null" or T-cell lymphomas may relfect differences in sensitivity to specific drugs.
 ...
PMID:Prognostic significance of lymphocyte surface markers in adult non-Hodgkin's malignant lymphoma. 6 5

Complexes of high-molecular-weight RNA and reverse transcriptase (RNA-dependent DNA nucleotidyltransferase) have been detected in 14(77.8%) of 18 spleen from patients with Hodgkin's disease and in all samples tested of peripheral leukocytes and spleens from leukemic patients. The enzyme and its template are localized in a particle having a density between 1.16 and 1.19 g/ml. These observations describe characteristic features of RNA tumor viruses.
 ...
PMID:Simultaneous detection of reverse transcriptase and high molecular weight RNA in tissue of patients with Hodgkin's disease and patients with leukemia. 6 53

88 patients with far-advanced lymphomatous malignancy were treated with Bleomycin given by either intramuscular (i. m.) or intravenous (i. v.) injection according to a randomized treatment assignment. Response occurred most frequently in Hodgkin's disease (i. m. 7/24; i. v. 4/18), least often in histiocytic lymphomas (i. m. 0/8; i. v. 1/8), and with intermediate frequency in lymphocytic lymphomas (i. m. 3/16; i. v. 0/14). While toxicity was common (70%), severe toxicity was unusual (8%) with severe pulmonary toxicity occurring in four patients (three i.m.; one i.v.). All three drug associated deaths occurred in i. m. patients. Unexpected life-threatening pericarditis occurred in two i. m. treated patients. Although response and drug related deaths occurred more often in the i. m. patients, the comparison with i. v. patients was not statistically different.
 ...
PMID:Treatment of advanced lymphomas with bleomycin (NSC-125066). 6 51


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>